The efficacy of transdermal fentanyl for pain relief after endoscopic submucosal dissection

Improvement of pain by therapeutic endoscopy in patients treated with transdermal fentanyl patch

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000421

Enrollment

100

Registered

2012-04-25

Start date

2010-05-03

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Fentanyl is a potent synthetic opioid agonist. We used 12 µg/h fentanyl patches (Duragesic® D-TRANS

Janssen Cliag GmbH, Germany) in this study. Placebo patches were made of the same size and appearance and with properties similar to the fentanyl patch. Patients received patches the night before the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were scheduled to undergo ESD for gastric epithelial neoplasm at Korea University Hospital

Exclusion criteria

Exclusion criteria: The exclusion criteria included 1) serious kidney disease that required drug dosage adjustment; 2) cardiopulmonary disease, endocrine disease, significant hepatic disease or hematologic disorder; 3) inability to perform gastroendoscopy; 4) diabetic neuropathy; 5) a history of drug or alcohol misuse; 6) severe psychiatric or neurological disease; 7) pregnant or nursing women; 8) opioid allergy; 9) dementia, and 10) impossible to assess pain.

Design outcomes

Primary

Measure	Time frame
pain scales after endoscopic submucosal dissection	—

Secondary

Measure	Time frame
amount of pain killer when patient wanted a pain killer	—

Countries

Korea, Republic of

Contacts

Public ContactHyuk Soon Choi

Korea University Anam Hospital

Outcome results